blood-cancer
Therapy-related acute myeloid leukemia (tAML) arises as a secondary malignancy from cancer treatments (chemotherapy, radiation). This Japanese study found that tAML incidence increased gradually but steadily over the past three decades, with rates almost tripling—driven by the growing population of…
blood-cancer
Leukemic stem cells (LSCs) drive AML relapse by resisting treatments targeting bulk tumor cells. This study found LSCs are specifically dependent on the PI3K alpha isoform (P110α). When PI3K is inhibited in AML cells, a compensatory resistance mechanism emerges: EZH2 protein is downregulated, and…
brain-cancer
Primary central nervous system lymphoma (PCNSL) is treated primarily with high-dose methotrexate (HD-MTX), but new agents presented at ASH 2025 are changing this paradigm. This editorial review summarizes key highlights: BTK inhibitors, immunomodulators, selinexor (an XPO1 inhibitor), and anti-PD-1…
blood-cancer
Systematic review of 29 phase 1-2 trials of non-engineered NK cell adoptive transfer in AML found: pooled 35% response rate in R/R AML (217 patients; 11 studies); 82% 1-year DFS in low-/intermediate-risk AML in remission; 40% 1-year DFS when combined with haploidentical HSCT. Toxicities were mild;…
blood-cancer
AML harboring BCR::ABL1 is classified as adverse-risk by European LeukemiaNet guidelines, but this classification was established before TKIs were routinely added to treatment. This real-world study of 57 BCR::ABL1 AML patients from the Spanish PETHEMA registry assessed whether TKI addition changes…
blood-cancer
The bone marrow microenvironment protects leukemia cells from both chemotherapy and immunotherapy, inhibiting T cell infiltration. This study addressed this by engineering CD33-targeted CAR-T cells to express constitutively active Rac1 (Rac1V12)—a GTPase that controls cell migration and tissue…
blood-cancer
Pediatric ALL survival rates are 80% in Argentina but below 60% in neighboring Paraguay, Peru, and Bolivia—driving medical migration. This retrospective study of 106 migrant children with ALL at a major Argentine center found stark disparities.
blood-cancer
Phase Ib study of TQB2618 (anti-TIM-3) + penpulimab (anti-PD-1) in 21 r/r cHL patients with prior PD-1/PD-L1 failure: 52% ORR (1 CR, 10 PR). TRAEs in 86%, grade ≥3 in 24%. Median duration of response and OS not reached at 14.1-month median follow-up.
blood-cancer
Phase 1 study of SAR445419 allogeneic NK cell therapy in 7 R/R AML patients (6 received treatment): no dose-limiting toxicities, two grade 2 infusion-related reactions (therapy-related). Five deaths, all from disease progression. No clinical responses observed. Study terminated early for strategic…
blood-cancer
Study of 407 lymphoma cases from Guatemala found SSTR2 expression in 43% of EBV-positive classical Hodgkin lymphoma vs. 0% of EBV-negative cHL. Other EBV-associated lymphomas were largely SSTR2-negative. In EBV-negative NHL, SSTR2 associated with higher-grade B-cell lymphomas (17% of DLBCL, 17%…
blood-cancer
CCDC137 is overexpressed in AML and correlates with poor prognosis. CCDC137 stabilizes S100A6 protein, which then activates the PI3K/AKT signaling pathway driving AML cell proliferation and cell cycle progression. This CCDC137→S100A6→PI3K/AKT axis is a novel AML therapeutic target.
blood-cancer
This protocol describes using CRISPR-Cas9 knockout screens to systematically identify genes mediating drug resistance in AML. Cells surviving better when a particular gene is deleted implicate that gene in resistance to cytarabine or venetoclax.